Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Химио- и радиотоксические поражения сердца у детей и подростков с онкогематологическими заболеваниями В.М.Делягин, Ю.В.Демидова, Е.А.Тихомирова ФГБУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева М
Химио- и радиотоксические поражения сердца у детей и подростков с онкогематологическими заболеваниями В.М.Делягин, Ю.В.Демидова, Е.А.Тихомирова ФГБУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева М
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Lanzkowsky Ph. Manual of pediatric hematology and oncology. 4th edition. Elseveir Inc., 2007.
2. Hoffman R, Benz E, Silberstein L et al. Hematology: Basic Principles and Practice, 6th edition. Elsevier Inc., 2013; p. 1452–68.
3. Lipshultz S, Landry D, Lopez-Mitnik G, Lipsitz S et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncology 2012; 30 (10): 1050–7.
4. Bovelli D, Plataniotis G, Rolia F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Ann Oncol 2010; 21 (Suppl. 5): 277–82.
5. Khanan-Khan A, Srinivasan Sh, Czuczman M. Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol 2004; 2 (3): 251–66.
6. Youseff G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs 2005; 5 (4): 233–43.
7. Bristow M, Thompson P, Martin R, Mason J et al. Early antthraciline cardiotixicity. Am J Med 1978; 65: 823–32.
8. Schwartz R, McKenzie W, Alexander J. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82: 1109–18.
9. Pfeffer B, Tziros C, Katz R. Current concepts of anthracycline cardiotoxicity: pathogenesis, diagnosis and prevention. Br J Cardiol 2009; 16 (2): 85–9.
10. Cyclophosphamide. URL: http://www.ehealthme.com/cyclophosphamide
11. Fulbright J. Review of cardiotixicity in pediatric cancer patients: during and after therapy. Cardiology Research and Practice. 2011; 1: 942090. DOI:10.4061/2011/942090.
12. Review: could Cisplatin cause Myocardial infarction? URL: http://www.ehealthme.com/ds/cisplatin/myocardial+infarction
13. Steinherz L, Graham T, Hurwitz R. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children’s Cancer Study Group. J Pediatrics 1992; 89: 942–9.
14. UK Clinical Guidelines for the Use of Adjuvant Trastuzumab (Herceptin) With or Following Chemotherapy in HER2-positive Early Breast Cancer. NCRI Breast Clinical Studies Group Clinical Studies Group. 14th December 2005. URL: http://www.dh.gov.uk/en/ Healthcare/NationalServiceFrameworks/Cancer/DH_4126383
15. Schwartz C, Hobbie W, Truesdell S et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 1993; 11: 1906–10.
16. Schmidt B, Sreeram N, Brockmeier K. Verlängerung des QTc-Intervalls im Oberflächen-Ekg. Pädiatrische Praxis 2009; 73: 279–86.
17. Roden D, Viswanathan P. Genetics of acquired long QT syndrome. J Clin Invest 2005; 115 (8): 2025–32.
18. Mori J, Sabel A, Sagar U, Carlin S et al. Factors influencing QT prolongation in patients hospitalized with severe anorexia nervosa. Gen Hosp Psychiatry 2012; 34: 173–7.
19. Nussinovitch M, Gur E. Kaminer K, Volovitz B et al. QT variability among weight-restored patients with anorexia nervosa. Gen Hosp Psychiatry 2012; 34: 62–5.
20. Tan T, Scherrer-Crosbie M. Assesing the cardiac toxicity of chemotherapeutic agents: role of echocardiography. Curr Cardiovasc Imaging 2012; 5 (6): 403–9.
21. Plana J. Chemotherapy and the heart. Rev Esp Cardiol 2011; 64 (5): 409–15.
22. Теплякова Е.Д. Формирование кардиоваскулярных осложнений у детей с острым лимфобластным лейкозом. Автореф. дис. … д-ра мед. наук. Р. н/Д, 2012.
23. Саржевский В.О., Колесникова Д.С., Вахромеева М.Н., Мельниченко В.Я. Кардиальные тропонины и высокодозная химиотерапия с аутологичной трансплантацией при лимфомах. Гематология и трансфузиология. 2014; 1 (Прил. 1): 116.
24. Lipshultz S, Miller T, Scully R, Lipstz S et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012; 30 (10): 1042–9.
25. Cardinale D, Sandri M, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749–54.
26. Koh E, Nakamura T, Takahashi H. Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circulation 2004; 68: 163–7.
27. Kavey R, Allada V, Daniels S. Cardio-vascular risk reduction in high-risk pediatric patients: A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research – Endorsed by the American Academy of Pediatric. Circulation 2006; 114: 2710–38.
28. Miller T, Lipsitz S, Lopez-Mitnik G. Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 2010; 19: 2013–22.
29. Silber J, Cnaan A, Clark B et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22 (5): 820–8.
30. Lee P, Mallik R. Cardiovascular rffects of radiation therapy: practical approaches to radiation therapy-induced heart disease. Cardiol Rev 2005; 13 (2): 80–6.
31. Jaworski C, Mariani Ju, Weeler G, Kaye D. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013; 61 (23): 2319–28.
32. Brenner D, Shuryak J, Jozsef G et al. Risk and risk reduction of major coronary events associated with contemporary breast radiotherapy. JAMA Intern Med 2014; 174 (1): 158–60.
2. Hoffman R, Benz E, Silberstein L et al. Hematology: Basic Principles and Practice, 6th edition. Elsevier Inc., 2013; p. 1452–68.
3. Lipshultz S, Landry D, Lopez-Mitnik G, Lipsitz S et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncology 2012; 30 (10): 1050–7.
4. Bovelli D, Plataniotis G, Rolia F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Ann Oncol 2010; 21 (Suppl. 5): 277–82.
5. Khanan-Khan A, Srinivasan Sh, Czuczman M. Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol 2004; 2 (3): 251–66.
6. Youseff G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs 2005; 5 (4): 233–43.
7. Bristow M, Thompson P, Martin R, Mason J et al. Early antthraciline cardiotixicity. Am J Med 1978; 65: 823–32.
8. Schwartz R, McKenzie W, Alexander J. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82: 1109–18.
9. Pfeffer B, Tziros C, Katz R. Current concepts of anthracycline cardiotoxicity: pathogenesis, diagnosis and prevention. Br J Cardiol 2009; 16 (2): 85–9.
10. Cyclophosphamide. URL: http://www.ehealthme.com/cyclophosphamide
11. Fulbright J. Review of cardiotixicity in pediatric cancer patients: during and after therapy. Cardiology Research and Practice. 2011; 1: 942090. DOI:10.4061/2011/942090.
12. Review: could Cisplatin cause Myocardial infarction? URL: http://www.ehealthme.com/ds/cisplatin/myocardial+infarction
13. Steinherz L, Graham T, Hurwitz R. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children’s Cancer Study Group. J Pediatrics 1992; 89: 942–9.
14. UK Clinical Guidelines for the Use of Adjuvant Trastuzumab (Herceptin) With or Following Chemotherapy in HER2-positive Early Breast Cancer. NCRI Breast Clinical Studies Group Clinical Studies Group. 14th December 2005. URL: http://www.dh.gov.uk/en/ Healthcare/NationalServiceFrameworks/Cancer/DH_4126383
15. Schwartz C, Hobbie W, Truesdell S et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 1993; 11: 1906–10.
16. Schmidt B, Sreeram N, Brockmeier K. Verlängerung des QTc-Intervalls im Oberflächen-Ekg. Pädiatrische Praxis 2009; 73: 279–86.
17. Roden D, Viswanathan P. Genetics of acquired long QT syndrome. J Clin Invest 2005; 115 (8): 2025–32.
18. Mori J, Sabel A, Sagar U, Carlin S et al. Factors influencing QT prolongation in patients hospitalized with severe anorexia nervosa. Gen Hosp Psychiatry 2012; 34: 173–7.
19. Nussinovitch M, Gur E. Kaminer K, Volovitz B et al. QT variability among weight-restored patients with anorexia nervosa. Gen Hosp Psychiatry 2012; 34: 62–5.
20. Tan T, Scherrer-Crosbie M. Assesing the cardiac toxicity of chemotherapeutic agents: role of echocardiography. Curr Cardiovasc Imaging 2012; 5 (6): 403–9.
21. Plana J. Chemotherapy and the heart. Rev Esp Cardiol 2011; 64 (5): 409–15.
22. Теплякова Е.Д. Формирование кардиоваскулярных осложнений у детей с острым лимфобластным лейкозом. Автореф. дис. … д-ра мед. наук. Р. н/Д, 2012.
23. Саржевский В.О., Колесникова Д.С., Вахромеева М.Н., Мельниченко В.Я. Кардиальные тропонины и высокодозная химиотерапия с аутологичной трансплантацией при лимфомах. Гематология и трансфузиология. 2014; 1 (Прил. 1): 116.
24. Lipshultz S, Miller T, Scully R, Lipstz S et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012; 30 (10): 1042–9.
25. Cardinale D, Sandri M, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749–54.
26. Koh E, Nakamura T, Takahashi H. Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circulation 2004; 68: 163–7.
27. Kavey R, Allada V, Daniels S. Cardio-vascular risk reduction in high-risk pediatric patients: A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research – Endorsed by the American Academy of Pediatric. Circulation 2006; 114: 2710–38.
28. Miller T, Lipsitz S, Lopez-Mitnik G. Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 2010; 19: 2013–22.
29. Silber J, Cnaan A, Clark B et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22 (5): 820–8.
30. Lee P, Mallik R. Cardiovascular rffects of radiation therapy: practical approaches to radiation therapy-induced heart disease. Cardiol Rev 2005; 13 (2): 80–6.
31. Jaworski C, Mariani Ju, Weeler G, Kaye D. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013; 61 (23): 2319–28.
32. Brenner D, Shuryak J, Jozsef G et al. Risk and risk reduction of major coronary events associated with contemporary breast radiotherapy. JAMA Intern Med 2014; 174 (1): 158–60.
Авторы
В.М.Делягин, Ю.В.Демидова, Е.А.Тихомирова
ФГБУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России, Москва
ФГБУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.